Title
Category
Credits
Event date
Cost
  • LivDerm
  • TME
  • AAPA Category I CME
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit
  • ANCC
  • Participation
$0.00
The increasing incidence of atopic dermatitis (AD) and poor recognition of the disease in some patient groups is a public health concern. AD symptoms and its daily management cause significant effects on quality of life for both patients and caregivers. Timely and adequate treatment of AD is essential for helping to promote better long-term outcomes and quality of life and may help prevent the development of other atopic conditions. However, the treatment of AD is a clinical challenge.
  • LivDerm
  • TME
  • AMA PRA Category 1 Credit
  • ANCC
  • Participation
$0.00
Pediatric patients with skin of color (SoC) can be disproportionately affected by a number of dermatologic conditions, including acne vulgaris, atopic dermatitis, and traction alopecia. It is imperative that providers are able to recognize and appropriately treat these conditions in their pediatric SoC patients. Going beyond basic treatment guidelines, there are steps clinicians can be taking to practice cultural sensitivity when treating patients and communicating with parents and caregivers.
  • LivDerm
  • TME
  • AMA PRA Category 1 Credit
  • ANCC
  • Participation
$0.00
Atopic dermatitis (AD) is a chronic inflammatory and relapsing cutaneous disease characterized by pruritus, cutaneous inflammation, and transepidermal water loss (Krakowski 2008).  The incidence of AD in industrialized nations has increased by three-fold over a 30-year span, and it is estimated to affect between 15% and 30% of children in industrialized nations (Bieber 2010).  Although most children with AD will “outgrow” the disease, AD has additionally been reported to affect up to 10% of adults, and recent research suggests that AD is under-recognized in this group (Bieber 2010; Silverbe
  • LivDerm
  • TME
  • AAPA Category I CME
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit
  • ANCC
  • Participation
$0.00
Timely and adequate treatment of atopic dermatitis (AD) is essential for helping to promote better long-term outcomes and quality of life. Targeted immunomodulatory agents, based on recent advances in the understanding of AD pathophysiology, represent additional options for long-term control. In particular, Janus kinase (JAK) inhibitors have emerged as a novel mechanism of action for treatment of AD.
  • LivDerm
  • TME
  • AMA PRA Category 1 Credit
  • ANCC
  • Participation
$0.00
Alopecia areata (AA) is an autoimmune disease that results in hair loss on the scalp and body. Currently,there is no FDA approved treatment for alopecia areata, challenging clinicians to find effectivetreatments in practice. However, recent findings have furthered understanding of AA, including thetargeting of specific immunologic pathways. Multiple clinical studies are underway investigating the useof Janus kinase (JAK) and TEC-family kinase inhibitors for treatment of moderate-to-severe AA.
  • LivDerm
  • TME
$0.00
**This activity has expired and is no longer eligible for CE credit. The content is still available to view.There is no doubt that clinicians have been exposed to more information about the human gut than ever before, and most practitioners treating skin disorders have had some form of education related to the skin microbiome.
  • LivDerm
  • TME
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit
  • ANCC
  • Participation
$0.00
Melanoma can be a life-threatening condition if left untreated. Patients with skin of color often face delays in diagnosis and treatment initiation in melanoma care. These disparities point to the need for increased awareness and education on melanoma risk and identification for clinicians and patients. Immunotherapies as mono and combination therapeutic regimens have become the gold standard in melanoma management.
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit
  • ANCC
  • Participation
$0.00
Addressing iron deficiency (ID) in patients with heart failure (HF) has become an important aspect of optimizing guideline-directed care in HF, as outlined by recent evidence and updated guidelines. During this webinar, expert faculty utilize challenging cases to discuss the importance of addressing ID in HF, as well as practical considerations for the diagnosis and treatment of ID in this setting.
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit
  • ANCC
  • Participation
$0.00
Iron deficiency (ID) with or without anemia is a common and important comorbidity in patients with heart failure (HF), and it can have significant impacts on morbidity and mortality.  Despite this burden, the diagnosis and assessment of ID is not widely sought by clinicians that see patients with HF, leading to underdiagnosis, misdiagnosis, and delayed treatment.  Recent trials and evidence have shown that i.v. iron repletion in HF patients with ID can improve symptoms, quality of life, and outcomes, and this evidence has been reflected accordingly in the updated HF guidelines.
  • LivDerm
  • TME
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit
  • ANCC
  • Participation
$0.00
Psoriatic arthritis (PsA) is a chronic, debilitating inflammatory disease that is associated with several comorbidities and often antecedes psoriasis. In fact, according to data from the National Psoriasis Foundation (NPF), approximately 30% of people with psoriasis develop PsA, with symptoms appearing around 10 years after the occurrence of cutaneous symptoms.

Pages